Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Provectus Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women, age 18 or older.
Mild, moderate or severe atopic dermatitis.
Presence of atopic dermatitis areas outside the head and face with a baseline Investigator Global Assessment (IGA) of 2 (mild disease), 3 (moderate) or 4 (severe disease) at screening.
Written informed consent by the subject or legal guardian.
You may not be if
Women who are pregnant, attempting to conceive, or nursing an infant.
Subjects who have received phototherapy (UVB, PUVA) or systemic therapy (immunosuppressants, cytostatics, corticosteroids) within 4 weeks.
Subjects who have received systemic antibiotics within 2 weeks.
Subjects who have received topical therapy (tar, corticosteroids) within 7 days.
Subjects who have received investigational drugs in a clinical research study within 4 weeks.
Subjects who have received agents posing a clinically significant risk of photosensitivity reaction within 5 half-lives of initiation of study treatment.
Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.
Subjects with clinical conditions that may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.
Clareo Health | A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis
